Gewinn- und Verlustrechnung von Patterson-UTI Energy, Inc.

HOUSTON, TX / ACCESS Newswire / August 14, 2026 / PATTERSON-UTI ENERGY, INC. (NASDAQ:PTEN) today reported that for the month of July 2026, the Company had an average of 98 drilling rigs operating in the United States.

Oil above $80 is boosting the outlook for Patterson-UTI and Cactus as Middle East tensions support crude prices and upstream activity.

Following a careful analysis of the Zacks Oil and Gas - Drilling industry, we advise focusing on companies like PTEN, NBR and HP.

The mean of analysts' price targets for Patterson-UTI (PTEN) points to a 37.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Here is how Patterson-UTI (PTEN) and SunCoke Energy (SXC) have performed compared to their sector so far this year.

BJ's Restaurants, Patterson-UTI Energy and BrightSpring Health Services stand out after recent broker upgrades, backed by projected solid 2026 earnings growth.

The headline numbers for Patterson-UTI (PTEN) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Patterson-UTI's longer contracts, higher dayrates and packed frac calendar point to better cash flow, but losses and commodity exposure remain.

First FDA-approved IHC assay identifies patients who may be eligible for combination treatment with TRUQAP® (capivasertib) BURLINGTON, N.C., Aug. 4, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced the nationwide availability of Roche's VENTANA® PTEN (SP218) RxDx Assay, the first immunohistochemistry (IHC) companion diagnostic test approved by the U.S. Food and Drug Administration (FDA) to determine PTEN protein loss, also known as PTEN deficiency, in tumors of patients with prostate adenocarcinoma.